2012
DOI: 10.1002/jmri.23628
|View full text |Cite
|
Sign up to set email alerts
|

MRI of cardiac iron overload

Abstract: Transfusion therapy has greatly improved the survival of transfusion dependent thalassemia major (TM) patients; however, the resultant iron load damages tissues including the heart, liver and endocrine organs. Among these, heart complication still remains the leading cause of mortality. Myocardial iron deposition can occur independently of other solid organ involvement; conversely, the heart may be spared despite heavy siderosis in other tissues. Iron chelation treatment diminishes the risk of hemosiderosis; h… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
18
0
3

Year Published

2013
2013
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 36 publications
(21 citation statements)
references
References 70 publications
0
18
0
3
Order By: Relevance
“…Hepatic fibrosis and cirrhosis may occur, but onset may be delayed compared to that observed in cases of increased intestinal absorption of iron. Cardiac toxicity is the greatest clinical concern in transfusional overload, and death often occurs from cardiomyopathy or cardiac arrhythmias .…”
Section: Mechanisms Of Iron Overloadmentioning
confidence: 99%
“…Hepatic fibrosis and cirrhosis may occur, but onset may be delayed compared to that observed in cases of increased intestinal absorption of iron. Cardiac toxicity is the greatest clinical concern in transfusional overload, and death often occurs from cardiomyopathy or cardiac arrhythmias .…”
Section: Mechanisms Of Iron Overloadmentioning
confidence: 99%
“…This morbidity and mortality is preventable provided adequate chelation therapy is instituted and maintained over time (i.e., tissue iron is kept within the target range, or if it excessive, lowered to the target range by use of an effective chelation strategy which the patient is willing and able to use). Three chelators are FDA approved in the US: deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), (approval years 1968, 2005, and 2011, respectively) . The era of widely available oral chelators began only in 2006, with the commercial launch of DFX.…”
Section: Introductionmentioning
confidence: 99%
“…An advantage of the proposed method over previous two‐point Dixon techniques for whole heart imaging is the possibility to obtain R 2 * maps in addition to the water and fat images. While the diagnostic utility of the fat image in the context of cardiac imaging is still debated , T 2 * (=1/R 2 *) is a well‐known and widely accepted biomarker of cardiac iron overload whose importance has been extensively reported in the literature . One of the major challenges inherent to cardiac T 2 * mapping is the wide spectrum of T 2 * values to be resolved.…”
Section: Discussionmentioning
confidence: 99%